pRxcision | Infectious Disease Artificial Intelligence

Bacterial diseases used to be the leading cause of death.

In 1920, the three leading causes of death - pneumonia, tuberculosis, and diarrhea - were all bacterial diseases. Eighty percent of bacterial pneumonia patients in America died.

cepia photo of a child hugging his grandmother

The miracle of antibiotics saved us.

Today, only 5% of pneumonia patients die. Because of antibiotics, the top ten causes of death in America do not include any bacterial disease. Antibiotics are the foundation of modern medicine.

Now we need to save antibiotics.

Due to antibiotic-misuse and -resistance, even our most powerful antibiotics are failing us. Today, tens of millions of patients worldwide are now at risk to die from a common infections like pneumonia, Typhoid, or diarrhea. A world without antibiotics is a world without safe surgeries, cancer treatments, organ transplants or treatments of chronic conditions like diabetes.

Bacterial diseases used to be the leading cause of death.

In 1920, the three leading causes of death - pneumonia, tuberculosis, and diarrhea - were all bacterial diseases. Eighty percent of bacterial pneumonia patients in America died.

The miracle of antibiotics saved us.

Today, only 5% of pneumonia patients die. Because of antibiotics, the top ten causes of death in America do not include any bacterial disease. Antibiotics are the foundation of modern medicine.

Now we need to save antibiotics.

Artificial Intelligence

Guide your patient's antibiotic regimen using artificial intelligence that leverages pharmacokinetics models, exposure-response relationships, pathogen data, and Monte Carlo simulation. pRxcision^TM feedback makes it easy for you to respond to changing clinical circumstances by continuously monitoring the Electronic Health Record (EHR), and identifying and integrating ever-changing clinical and microbiological data.

EHR Integration
pRxcisionTM seamlessly and securely receives and synchronizes  patient-specific characteristics and laboratory results.
Antibiotics
Our growing pRxcisionTM library contains over 80 intravenous and oral antibiotics. 
Infection
A broad-range of community- and healthcare-onset infections are supported by pRxcisionTM. 
Susceptibility Data
Local, regional, and national pathogen-antibiotic susceptibility data help pRxcisionTM inform antibiotic regimen decisions.

‍
PK-PD Ranked Antibiotic Regimens
Helps identify and compare antibiotic regimens. 

The result? pRxcisionTM helps you prescribe the right drug, at the right dose, for the right duration faster than ever before possible. 

Pharmacokinetic Models

Inform initial antibiotic therapy, which is updated continuously through pRxcision^TM.

Pathogens

pRxcision^TM-assisted empiric therapy prioritizes the most common pathogens based upon infection type, while targeted therapy is guided by continuously updated microbiological data.

PK-PD Target

Antibiotic PK-PD targets derived from exposure-response relationships helps pRxcision^TM inform antibiotic regimen decisions.

Monte Carlo Simulation

pRxcision^TM integrates pharmacokinetic, PK-PD targets, and susceptibility data to estimate each antibiotic regimen's probability of attaining the PK-PD target.

The pRxcision™ Platform

Designed with the end in mind — unprecedented insight into antibiotic therapy decisions.

The Science behind pRxcision

Technology developed from over 20 years of research at ICPD

ICPD: The Institute for Clinical Pharmacodynamics

Founded: in 2004 by Drs. Paul Ambrose, Sujata Bhavnani and Chris Rubino

Experience: Founders have nearly 100 years of clinical practice, pharmaceutical company and entrepreneurial experience

Mission: To change the way antimicrobial
agents are developed and used for the care of patients worldwide

Influence: Recognized by industry, academics,and clinicians as leaders in pharmacology, drug development, and optimal use of antimicrobial agents

Trust: Collaborated with and/or advised
academics, drug developers, and regulators
from the United States, Europe and Asia

THE TEAM

Experts in Infectious Disease Pharmacology and Technology

Paul G. Ambrose

Pharm.D., FIDSA Co-founder and Chief Executive Officer

Paul serves as President of ICPD in Schenectady, NY. Dr. Ambrose's areas of scientific inquiry primarily involve anti-infective translational science, with the goal of improving patient care through the application of PK-PD principles. He received his Pharm. D. from the University of the Pacific and completed a Post-Doctoral Fellowship in infectious diseases at Hartford Hospital. Dr. Ambrose has held academic appointments at the University of Oxford and the University at Buffalo. Winner of the 2019 Antibiotic Lecture, a lifetime achievement award of the American Society of Microbiology.

read less

Christopher M. Rubino

Pharm.D., Co-Founder, Chief Science Officer, and Chairman

Chris serves as the Executive Vice- President of Pharmacometrics for ICPD in Buffalo, NY and an Adjunct Assistant Research Professor at the University at Buffalo. Dr. Rubino has served as a resource for pharmaceutical firms during the submission of adult- and pediatric- related filings to the FDA and EMA across several therapeutic areas. He received his B.Sc. in Pharmacy from the University of Connecticut, his Pharm. D. from the University at Buffalo, and completed a two-year post doctorial fellowship in pediatric pharmacology at the Women's Hospital of Greensboro.

read less

Sujata M. Bhavnani

Pharm.D., M.S. Co-Founder and Chief
Translational Medicine Officer

Sujata serves as Executive Vice- President of Translational Medicine for ICPD in Schenectady, NY. Dr. Bhavnani has extensive experience evaluating exposure-response relationships for antimicrobial agents using pre-clinical and clinical data. Her analyses have supported numerous New Drug Applications in the USA and around the world. She received her B.Sc. in Pharmacy from the University of Toronto, her Pharm. D. from the Albany College of Pharmacy, completed a two-year post doctorial fellowship in infectious diseases and pharmacokinetics at Millard Fillmore Hospital, and her M.S. in biometry from the University at Buffalo.

read less

Mark Gibelli

Chief Technology Officer

Mark is a seasoned technology executive with deep hands-on experience architecting and developing solutions for the healthcare industry. Mark co- founded AssuriCare in 2010, developing the cloud-based SaaS platform which served tens of thousands of users. Prior to AssuriCare, Mark founded StoryBoard Consulting in 2007, and co-founded Extrio Corporation, both technology consultancies. Mark's additional experience includes work with the University of Miami and Cambridge Technology Partners.

read less

TESTIMONIALS

Thomas Lodise PharmD, PhD

Professor, Pharmacy Practice
Albany College of Pharmacy and Health Sciences
Albany, NY

“pRxcision is one of the notable achievements in PK-PD over the past 50 years. For the first time, clinicians will have a mechanism to dose optimize antimicrobial agents at the bedside in real-time...I can’t wait to use this app in my clinical practice!”

Keith Rodvold PharmD

Distinguished Professor, Pharmacy Practice
University of Illinois, Chicago, College of Pharmacy
Chicago, IL

"...pRxcision will rapidly become an integral part of antibiotic stewardship programs as well as provide clinicians with up-to-date information to appropriately prescribe antibiotics.”

George L. Drusano MD

Director, Institute for Therapeutic Innovation
Department of Medicine,
University of Florida College of Medicine,
Orlando, Florida

“An important contribution to infectious disease chemotherapy and antibiotic stewardship…this tool will help save lives.”

David Andes MD

Chief, Division of Infectious Diseases
University of Wisconsin School of Medicine and Public Health
William A. Craig Endowed Professorship
Madison, Wisconsin

“pRxcision provides an advanced level of antibiotic selection and dosing decision support for our patients as well as a valuable teaching tool.”

Saving the miracle.^™

Bacterial diseases used to be the leading cause of death.

The miracle of antibiotics saved us.

Now we need to save antibiotics.

Bacterial diseases used to be the leading cause of death.

The miracle of antibiotics saved us.

Now we need to save antibiotics.

Sounding the
Alarm

Sounding the
Alarm

Introducing

pRxcision^™

Therapeutic Drug Monitoring

Most expansive antibiotic library

Infection-specific PK-PD targets, applied across 29 infections

Informed empiric therapy

Truly individualized approach to antimicrobial selection and dosing

Ability to select multiple pathogens for PK-PD calculations

Customized to your formulary, your antibiogram

ICPD Expertise